Ellipses Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ellipses Pharma sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Ellipses Pharma: 3 sponsored US clinical trials, 2 recruiting.
Ellipses Pharma sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hormone Receptor Positive HER-2 Negative Breast Cancer, with 1 trials.
Upper-quartile sponsor footprint
Ellipses Pharma sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
NCT05443126
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
NCT04669002
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
What is open in the Ellipses Pharma pipeline
2 recruiting of 3 indexed (67% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Hormone Receptor Positive HER-2 Negative Breast Cancer (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ellipses Pharma: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Ellipses Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Ellipses Pharma page
3 registered trials is a research-attention snapshot, not an endorsement of Ellipses Pharma or any single study.
- 2 of Ellipses Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hormone Receptor Positive HER-2 Negative Breast Cancer is the condition Ellipses Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hormone Receptor Positive HER-2 Negative Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ellipses Pharma pipeline card: 3 registered trials from official public datasets.Report a data error.